NMDA receptor antagonists: A new therapeutic approach for Alzheimer's disease

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Research into Alzheimer's disease (AD) pathology has identified several underlying disease processes that are potential targets for drug discovery and development. One strategy targets glutamatergic neurotransmission mediated by the N-methyl-D-aspartate (NMDA) receptor. Therapeutic intervention with high-affinity NMDA receptor antagonists, such as phencyclidine (PCP) and MK-801, is not practical due to adverse side effects; however, a low-moderate affinity, uncompetitive and strongly voltage-dependent NMDA receptor antagonist, memantine (Namenda™), is well tolerated and recently has been approved by the U.S. Food and Drug Administration for the treatment of moderate to severe AD. Clinical results support NMDA receptor antagonism as a viable therapeutic strategy for AD and suggest that this novel pharmacologic approach, either alone or in combination with other drugs, is likely to significantly impact the current AD treatment paradigm.

Original languageEnglish
Pages (from-to)22-27
Number of pages6
JournalGeriatrics
Volume59
Issue number6
StatePublished - Jun 2004

Fingerprint

N-Methyl-D-Aspartate Receptors
Alzheimer Disease
Memantine
Phencyclidine
Dizocilpine Maleate
Drug Discovery
United States Food and Drug Administration
Therapeutics
Synaptic Transmission
Pathology
Research
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Cholinesterase
  • Inhibitors
  • Memantine
  • NMDA receptor antagonist

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

NMDA receptor antagonists : A new therapeutic approach for Alzheimer's disease. / Farlow, Martin.

In: Geriatrics, Vol. 59, No. 6, 06.2004, p. 22-27.

Research output: Contribution to journalArticle

@article{31967645c870413eaf3df5b96f340425,
title = "NMDA receptor antagonists: A new therapeutic approach for Alzheimer's disease",
abstract = "Research into Alzheimer's disease (AD) pathology has identified several underlying disease processes that are potential targets for drug discovery and development. One strategy targets glutamatergic neurotransmission mediated by the N-methyl-D-aspartate (NMDA) receptor. Therapeutic intervention with high-affinity NMDA receptor antagonists, such as phencyclidine (PCP) and MK-801, is not practical due to adverse side effects; however, a low-moderate affinity, uncompetitive and strongly voltage-dependent NMDA receptor antagonist, memantine (Namenda™), is well tolerated and recently has been approved by the U.S. Food and Drug Administration for the treatment of moderate to severe AD. Clinical results support NMDA receptor antagonism as a viable therapeutic strategy for AD and suggest that this novel pharmacologic approach, either alone or in combination with other drugs, is likely to significantly impact the current AD treatment paradigm.",
keywords = "Alzheimer's disease, Cholinesterase, Inhibitors, Memantine, NMDA receptor antagonist",
author = "Martin Farlow",
year = "2004",
month = "6",
language = "English",
volume = "59",
pages = "22--27",
journal = "Geriatrics",
issn = "0016-867X",
publisher = "Advanstar Communications",
number = "6",

}

TY - JOUR

T1 - NMDA receptor antagonists

T2 - A new therapeutic approach for Alzheimer's disease

AU - Farlow, Martin

PY - 2004/6

Y1 - 2004/6

N2 - Research into Alzheimer's disease (AD) pathology has identified several underlying disease processes that are potential targets for drug discovery and development. One strategy targets glutamatergic neurotransmission mediated by the N-methyl-D-aspartate (NMDA) receptor. Therapeutic intervention with high-affinity NMDA receptor antagonists, such as phencyclidine (PCP) and MK-801, is not practical due to adverse side effects; however, a low-moderate affinity, uncompetitive and strongly voltage-dependent NMDA receptor antagonist, memantine (Namenda™), is well tolerated and recently has been approved by the U.S. Food and Drug Administration for the treatment of moderate to severe AD. Clinical results support NMDA receptor antagonism as a viable therapeutic strategy for AD and suggest that this novel pharmacologic approach, either alone or in combination with other drugs, is likely to significantly impact the current AD treatment paradigm.

AB - Research into Alzheimer's disease (AD) pathology has identified several underlying disease processes that are potential targets for drug discovery and development. One strategy targets glutamatergic neurotransmission mediated by the N-methyl-D-aspartate (NMDA) receptor. Therapeutic intervention with high-affinity NMDA receptor antagonists, such as phencyclidine (PCP) and MK-801, is not practical due to adverse side effects; however, a low-moderate affinity, uncompetitive and strongly voltage-dependent NMDA receptor antagonist, memantine (Namenda™), is well tolerated and recently has been approved by the U.S. Food and Drug Administration for the treatment of moderate to severe AD. Clinical results support NMDA receptor antagonism as a viable therapeutic strategy for AD and suggest that this novel pharmacologic approach, either alone or in combination with other drugs, is likely to significantly impact the current AD treatment paradigm.

KW - Alzheimer's disease

KW - Cholinesterase

KW - Inhibitors

KW - Memantine

KW - NMDA receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=3042725543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042725543&partnerID=8YFLogxK

M3 - Article

C2 - 15224791

AN - SCOPUS:3042725543

VL - 59

SP - 22

EP - 27

JO - Geriatrics

JF - Geriatrics

SN - 0016-867X

IS - 6

ER -